Typically triple-negative for hormone receptors and human epidermal growth factor receptor 2 (HER2), BMCA paradoxically demonstrates a better prognosis compared to other triple-negative breast cancers. This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.